<span class="paragraphSection"><div class="boxTitle">Abstract</div>We argue that the current ethical and regulatory framework for permissible risk levels in pediatric research can be helpfully understood in terms of children’s moral right to adequate protection from harm. Our analysis provides a rationale for what we propose as the highest level of permissible risk in pediatric research without the prospect of direct benefit: what we call “relatively minor” risk. We clarify the justification behind the usual standards of “minimal risk” and “a minor increase over minimal risk” and explain why it is permissible to impose any risks at all on child participants who do not stand to benefit directly from enrollment in research. Finally, we illuminate some aspects of the concept of “best interests.”</span>
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2pYXsXv
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Background Hyperthyroidism is associated with increased thrombotic risk. As contact system activation through formation of neutrophil extrac...
-
Abstract Helmet manufacturers recommend replacing a bicycle helmet after an impact or after anywhere from 2 to 10 years of use. The goal o...
-
Caring for Patients with Physical Disabilities: Assessment of an Innovative Spinal Cord Injury Session that Addresses an Educational Gap Des...
-
Abstract Objective To evaluate Chinese medicine (CM) formula Bazheng Powder (八正散) as an alternative therapeutic option for female patients...
-
Abstract Electro-Fenton (EF), an advanced oxidation process, can be combined with a biological process for efficient treatment of wastewate...
-
ACS Nano DOI: 10.1021/acsnano.6b07082 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2j1vZRU via...
-
ABSTRACT Polygenic scores (PGS) summarize the genetic contribution of a person's genotype to a disease or phenotype. They can be used ...
-
bmj;356/mar29_1/j1571/FAF1faKunal Patel/Hindustani Times/Getty ImagesNearly 40 000 doctors in Delhi and Mumbai have gone on strike to demand...
-
Abstract Background Volasertib, a potent and selective polo-like kinase inhibitor, has shown to increase response rates and improve surv...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου